Related Experiment Video
Updated: Jun 17, 2026
Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
[Application of neoadjuvant chemotherapy for operable breast cancer]
Lin Zheng1, Hai-yan Gao, Xiao-lan Zhang
1Department of Breast Surgery, Second People's Hospital of Changzhou, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China. dragon1603@163.com
Objective:
To investigate the clinical value of neoadjuvant chemotherapy in the treatment of operable breast cancer.
Methods:
A total of 120 patients with pathologically proven operable breast cancer were randomized into two groups to receive 2-4 cycles of neoadjuvant chemotherapy with docetaxel combined with pirarubicin (TThp) or docetaxel combined with epirubicin (TE). Operations were performed two weeks after the neoadjuvant chemotherapy. The short-term therapeutic effect, toxic reaction and the impact of neoadjuvant chemotherapy on the choice of surgical approaches were evaluated.
Results:
The total effective rate for the primary sites was 87.2% in these patients, and the rate of breast conservation significantly increased from 12.7% to 41.8% (P<0.05), with a tumor resection rate of 97.2%. The major adverse effects of the therapy included leukopenia, nausea, vomiting and alopecia.
Conclusion:
Neoadjuvant chemotherapy can enhance the breast conservation rate, lower the clinical staging of the tumors and minimize the surgery area to improve the postoperative quality of life of the patients.